KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC): Updated response and survival results Meeting Abstract
| Authors: | O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D. E.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; Savage, M. J.; Fang, X.; Godwin, J. L.; Frenkl, T. L.; De Wit, R. |
| Abstract Title: | KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC): Updated response and survival results |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 275s |
| Language: | English |
| ACCESSION: | WOS:000487345805369 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4546 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4546 -- Source: Wos |
